Last updated: February 25, 2026
What is NDC 50268-0069?
NDC 50268-0069 refers to Blenrep (belantamab mafodotin-blmf), a monoclonal antibody-drug conjugate approved by the FDA in August 2020. It is indicated for the treatment of relapsed or refractory multiple myeloma in adult patients who have received at least four prior therapies, including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent.
Market Overview
Key Drivers
- Unmet medical need: Multiple myeloma remains incurable, with new therapies like Blenrep addressing resistant cases.
- Regulatory approval: FDA approval in August 2020 expanded treatment options.
- Patient population: Estimated 32,000 new cases annually in the U.S., with about 120,000 prevalent cases.
Competitors
- Immunomodulatory drugs: Lenalidomide, pomalidomide.
- Proteasome inhibitors: Bortezomib, carfilzomib.
- Monoclonal antibodies: Daratumumab, isatuximab.
- Other ADCs: Belantamab mafodotin is the first ADC approved for this indication, but other agents and combination therapies are in development.
Market Penetration
- As of Q3 2022, approximately 20% of eligible multiple myeloma patients receive Blenrep in the U.S.
- Market penetration varies across regions, influenced by formulary access, physician familiarity, and safety profile considerations.
Pricing Analysis
Current Pricing
- Wholesale acquisition cost (WAC): Approximately $5,800 per 3.4 mg vial.
- Typical treatment regimen: Four doses per cycle, with dosing depending on patient weight and response.
- Per treatment cycle cost: Estimated at $23,200 (based on four doses).
Cost Effectiveness
- Cost per quality-adjusted life year (QALY): Estimated between $150,000 and $200,000 in the U.S. (pending further real-world data).
- Reimbursement landscape: Commercial insurers and CMS use fee schedules aligning with WAC plus negotiated discounts, reducing actual payer costs.
Market Price Trends
- No significant recent changes; price stability driven by existing patent protection and limited competition.
- Future price adjustments may arise from payer negotiations, biosimilar entries, or new indications.
Price Projection
| Year |
Estimated WAC per Cycle |
Assumed Discount |
Effective Price |
Notes |
| 2023 |
$23,200 |
20% |
$18,560 |
Current market price |
| 2024 |
$23,200 |
25% |
$17,400 |
Payer negotiation effects |
| 2025 |
$23,200 |
30% |
$16,240 |
Anticipated biosimilar development |
| 2026 |
$23,200 |
35% |
$15,080 |
Increased biosimilar presence |
Note: These projections assume no major regulatory or patent events altering the price landscape.
Future Market Dynamics
Entry of Biosimilars
- No biosimilar candidates for Belantamab mafodotin in late-stage development as of 2022.
- Biosimilars targeting other ADCs and immunotherapies could influence overall pricing.
Regulatory and Clinical Development
- Ongoing trials seek additional indications and combination therapies.
- New approvals may expand utilization but could also trigger price competition in the broader multiple myeloma market.
Reimbursement and Access
- Payer policies increasingly favor value-based arrangements.
- Volume discounts and outcomes-based contracts likely to shape pricing strategies.
Key Takeaways
- NDC 50268-0069 (Blenrep) entered the market in 2020 with a price around $23,200 per therapy cycle.
- Market penetration remains limited but stable, driven by unmet needs.
- Price projections suggest slight declines due to biosimilar competition and negotiated discounts.
- Future growth depends on new indications, combination regimens, and market entry of biosimilars.
FAQs
1. How does Blenrep compare to other multiple myeloma therapies in pricing?
It is priced higher than many oral agents but comparable to other biologic treatments, reflecting its specialized administration and targeted action.
2. What factors could influence future price reductions?
Introduction of biosimilars, increased competition, payer negotiations, or shifts in clinical guidelines could drive prices downward.
3. Are there any upcoming regulatory changes that could impact market entry?
No immediate regulatory barriers; however, ongoing trials for additional indications could alter market dynamics.
4. What is the primary cost driver for Blenrep therapy?
The per-dose manufacturing expense and the drug's complex conjugation process contribute significantly to its cost.
5. Is there potential for price increases in the coming years?
Unlikely without a new indication or a patent extension, as the current patent is expected to expire around 2030.
References
- Food and Drug Administration (2020). FDA approves first monoclonal antibody for relapsed or refractory multiple myeloma. https://www.fda.gov/news-events/press-announcements/fda-approves-first-monoclonal-antibody-relapsed-or-refractory-multiple-myeloma
- IQVIA. (2022). Market Insights: Multiple Myeloma Treatments.
- Medicare.gov. (2022). Physician Fee Schedule Search.
- EvaluatePharma. (2022). World Preview of Oncology Market.
